Zydus Cadila receives final approval from USFDA for Fluphenazine Hydrochloride Tablets

Zydus Cadila has received final approval from the USFDA to market Fluphenazine Hydrochloride Tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (US RLD: Prolixin Tablets). This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia). Fluphenazine belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.621.25 as compared to the previous close of Rs. 626.7. The total number of shares traded during the day was 336904 in over 8038 trades.

The stock hit an intraday high of Rs. 628.1 and intraday low of 612.65. The net turnover during the day was Rs. 208823261.

Source : Equity Bulls

Keywords